Botulinum Toxin: Market Research Report
This report analyzes the worldwide markets for Botulinum Toxin in US$ Million by the following Product Segments: Cosmetic Applications, and Therapeutic Applications. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.The report profiles 22 companies including many key and niche players such as Allergan, Inc., Ipsen Group, Lanzhou Institute of Biological Products, Metabiologics, Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, Medy-Tox Incorporated, Medicis Pharmaceutical Corporation, Revance Therapeutics, Inc., and US WorldMeds. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONSStudy Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Cosmetic Applications
Therapeutic Applications
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
A Prelude
Current and Future Scenario
By Geographic Region
Botulinum Toxin: “The Science, The Hopes & the Risks”
Developed Regions Continue to Hold Sway Over Global Botulinum Toxin Market
Developing Markets Not Far Behind, But Not Yet There…
Pharma Companies Keenly Eye Lucrative BT Market
2. TRENDS & ISSUES
Acceptance for Cosmetic BTX Treatment Grows
Aging Population: A Weighty Demographic Driver
Unmet Medical Needs Encourage Off-Label Use: A Cause for Concern or Jubilation?
Urgent Need for Physician Education about Off Label Usage
High Voltage Ad Campaigns Boost Patient Awareness
Societal Pressure to Look Young, Drives up Demand for Facial Aesthetics
Financing of Non-Reimbursed Healthcare: The Need of the Hour
Combination Therapies: A Double Whammy Success
Short Lived Aesthetic Effects: A Strong Business Case for Revision Treatments
Consolidation Blows in the Aesthetic Healthcare Industry
Undesirable Side Effects: A Challenge to Reckon With
Immunogenicity Undermines Patient Compliance
Protein Free BTX Products – The Probable Answer for Immunogenicity
Antigenicity: One of the Most Problematic Issues in Drug Development
Stringent Regulations Delay Market Approval & Put Reimbursements in Limbo
Non-Injectable Alternatives to Turn On the Heat
Alternative Methods of Botulinum Application under Development – A Review
Fears of Terrorism & Biological Warfare Thwart International Trade
3. PRODUCT/INDUSTRY DYNAMICS
Comparison of Botox®, Dysport® and Xeomin® by Indications and Year of Approval
Scarce Differentiation Between the Four Approved BTX Products
Comparison of Leading Neurotoxins – Botox, Dysport and Xeomin by Safety and Efficacy
Botox® - An Overview
Key Characteristics of Botox® and Botox® Cosmetic
Common Adverse Reactions with Botox
Approvals and Indications of Botox in Select Regions
Global Botox Sales Shoot Up, Competition Begins to Hurt Prospects
Migraine Indication to Bolster Allergan’s Botox Sales
Allergan Commences Advertising for Botox in Migraine Settings in the US
Therapeutics to Offer Higher Prospects for Botox
Botox Therapeutic Approvals in the US by Indication
Dysport®
Key Characteristics of Dysport®
Ipsen Counts on New Indications for Future Growth of Dysport
Dysport Therapeutic Development Pipeline by Region
Dysport Cosmetic Development Pipeline by Region
Next Generation Dysport – A Breakthrough in BTX Market on the Cards
Xeomin®
Key Characteristics of Xeomin®
Xeomin Development Pipeline: Approved and Investigational Indications as of 2011
Global Expansion Helps Merz Gain in the BTX Market
Myobloc®/NeuroBloc®
Key Characteristics of Myobloc®
Myobloc – Still Long Way to Go…
Meditoxin®
Meditoxin® Expanding Its Wings across the Globe
PurTox®
Key Characteristics of PurTox®
PurTox Beckons Success in Clinical Trial Stage, Launch Still Years Away
RT001
Revance’s RT001 –Potential Revolution in BTX Market under Development
How Does RT001 Work?
RT001 – A Potential Convenient Treatment Option for Hyperhydrosis Patients
4. COMPETITION
Allergan Wields the Scepter
Allergan’s Botox Faces the Heat of Competition
Market Share Statistics
Global
Table 1: Leading Products in the Global Botulinum Toxin Market (2011E): Percentage Breakdown of Revenue for Botox, Dysport, Xeomin and Others (includes corresponding Graph/Chart)
Table 2: World Market for Therapeutic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand –Botox, Dysport, Xeomin and Others (includes corresponding Graph/Chart)
Table 3: World Market for Cosmetic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand – Botox, Dysport, Xeomin and Others (includes corresponding Graph/Chart)
5. PRODUCT OVERVIEW
Botulinum Toxin: A Poison That Cures
Structure & Mechanism of Action
Disadvantages
Classification of Botulinum Toxin
Botulinum Toxin Type A
Historical Timeline of Botulinum Toxin: 1885-2002
Botulinum Toxin Type B
Applications of Botulinum Toxin
Cosmetic Applications
Glabellar Lines
Facial Wrinkles
Key Cosmetic Indications for Botulinum Toxin
Therapeutic Applications
Movement Disorders/Pain
Cervical Dystonia
Hemifacial Spasm
Blepharospasm
Strabismus
Chronic Pain
Botox in Migraine Treatment
Hyperhidrosis
Bladder Dysfunctions
Spasticity
Other Applications
Side Effects
An Overview of Side Effects of BTX Treatment
Table 4: Side-Effects of BOTOX Treatment for Urinary Incontinence Associateh Neuromuscular Disorders: Percentage Breakdown of Major Conditions Reported Within 12 weeks of Injections during Phase III Clinical Trials (includes corresponding Graph/Chart)
Table 5: Side-Effects of BOTOX Treatment for Urinary Incontinence Associated with Neuromuscular Disorders: Percentage Breakdown of Major Conditions Reported Within 44 weeks of Injections during Phase III Clinical Trials (includes corresponding Graph/Chart)
6. PRODUCT INTRODUCTIONS/APPROVALS
Botox Receives Health Canada Approval for Treating Neurogenic Bladder Condition
Allergan Obtains FDA Approval for New In –Vitro Cell-Based Assay for BOTOX
Merz Aesthetics Obtains FDA Approval for XEOMIN® for Treating Glabellar Lines
IMB Recommends Botox for Urinary Incontinence Management in Neurognenic OAB in EU
FDA Approves Botox for Treating Urinary Incontinence in Neurogenic OAB Patients
Allergan Receives Health Canada Approval for Botox for Treating Chronic Migraine
BOTOX® Receives Approval for Treating Chronic Headaches
Eisai’s NerBloc Intramuscular Injection Approved for Sale in Japan.
SMC Approves the Use of Botox® for the Treatment of Focal Spasticity
FDA Grants Approval for Botox for Treating Migraine
MHRA Grants Approval for Botox for Treating Chronic Migraine
Allergan Receives FDA Approval for Botox for Treating Upper Limb Spasticity
Russian Authorities Approve Xeomin for Cosmetic Applications
Merz Launches Xeomin in the US
Ipsen Launches Dysport in US
Ipsen and Medicis Receives FDA Approval for Dysport™
Xeomin Receives Approval From European Health Authorities
Ranbaxy and MedyTox Collaborates to Launch Neuronox
GlaxoSmithKline Receives Approval for Botox Vista
Galderma and Ipsen Obtain Marketing Authorization for Azzalure
Azzalure® Gains Approval from 15 European Countries
Inclusion of New Side Effect in Botox and Botox Cosmetic Labels
Azzalure® Gains Approval for Aesthetic Application in the UK
Allergan and Clinique Launch New Skin Care Products
FDA Accepts Ipsen's Filing for Reloxin
GlaxoSmithKline Gains Approval for BOTOX® in Japan
Mentor Completes Phase IIIb Trial for Its Botulinum Toxin Type A Product
Allergan Commences Botox Study for Urological Cases in India
FDA Accepts BLA Filing for Dysport® in Cervical Dystonia Cases
Allergan Successfully Completes Analysis of Two Phase III Trials for BOTOX®
Allergan to Launch New Products in India
7. RECENT INDUSTRY ACTIVITY
Amgen Inc Acquires Brazilian Company Bergamo
Ipsen and Syntaxin Forge Agreement to Formulate Novel Botulinum Toxin Product
Xoma Bags Federal Contract to Develop Broad-Spectrum Antitoxins
US WorldMeds Takes Over Solstice Neurosciences
Merz Pharma Acquires BioForm Medical
Johnson & Johnson Acquires Mentor Corporation
Merz Pharmaceuticals and Biolab Set Up Joint Venture
Ranbaxy Signs an in-Licensing Agreement with Medy-Tox
Ranbaxy Signs Marketing Agreement with MedyTox
Revance and Medicis Sign Licensing Agreement
GlaxoSmithKline and Wakamoto Pharmaceutical Collaborate to Market Botox
BioForm Medical Acquires Advanced Cosmetic Intervention
Galderma to Acquire CollaGenex
Allergan and Clinique Form Strategic Collaboration
Allergan to Set Up a New Subsidiary in India
Allergan Join Hands with India–Based Kaya
Q-Med and Medy-Tox Cancel the Collaboration Agreement
Galderma to Increase Awareness in Brazil
Galderma Receives License to Market Dysport
8. FOCUS ON SELECT GLOBAL PLAYERS
Allergan, Inc. (US)
Ipsen Group (France)
Lanzhou Institute of Biological Products (China)
Metabiologics, Inc. (US)
Merz Pharma GmbH & Co. KGaA (Germany)
Mentor Corporation (US)
Medy-Tox Incorporated (South Korea)
Medicis Pharmaceutical Corporation (US)
Revance Therapeutics, Inc. (US)
US WorldMeds (US)
9. GLOBAL MARKET PERSPECTIVE
Table 6: World Recent Past, Current & Future Analysis for Botulinum Toxin by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 7: World Historic Review for Botulinum Toxin by Geographic Region/Country – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million For the Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 8: World 15-Year Perspective for Botulinum Toxin by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
Table 9: World Recent Past, Current & Future Analysis for Botulinum Toxin in Cosmetic Applications by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 10: World Historic Review for Botulinum Toxin in Cosmetic Applications by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 11: World 15-Year Perspective for Botulinum Toxin in Cosmetic Applications by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
Table 12: World Recent Past, Current & Future Analysis for Botulinum Toxin in Therapeutic Applications by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 13: World Historic Review for Botulinum Toxin in Therapeutic Applications by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed by Annual Sales in US$ Million for the Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 14: World 15-Year Perspective for Botulinum Toxin in Therapeutic Applications by Geographic Region – Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
III. MARKET
1. THE UNITED STATES
A. Market Analysis
Current and Future Scenario
Cosmetic Procedures: An Overview
Major Market Trends
Botulinum Toxin to Drive Growth in the Facial Aesthetics Market
Competition Heats Up in the US BTX Market
Booming Non-Surgical Treatments
Aging Baby Boomers Drive Aesthetic Business
Expanding Physician Base Extends Impetus to Growth
Demand for Professional Help On the Rise
Direct-to-Consumer Advertising Drive Cosmetic Botulinum Toxin
Botulism Poisoning: A Major Concern
Botox Injection – Popular Non-Invasive Cosmetic Procedure
Recession Dents Cosmetic BTX Procedural Volume, Albeit Slightly
Table 15: US Cosmetic BTX Procedure Volume: 2007-2011 (includes corresponding Graph/Chart)
Botox Therapeutic to Drive Growth in Botox Franchise
Dysport Takes on Botox in the Therapeutic Space
Pricing and Promotions to Help Dysport Gain Market Share in Cosmetic Arena
Tremendous Prospects in Therapeutics Space for Dysport in the Long Run
Therapeutic BTX Market – New Entrants Slow in Gaining Market Share
Botox’s Therapeutic Indications (Approved and Investigational) in the US by Year of Approval/Stage
Cosmetic BTX Market – Competition Threatens Botox Long-Term Dominance
Key BTX Products and Associated Fillers and Implants in the Cosmetic Botulinum Toxin Market
Market Opportunities for Botox in Migraine Beckons a Slow Star
Neurogenic OAB – A Relatively Smaller Market Opportunity
Idiopathic OAB Bodes Superior Prospects for Botox
Issues Persist in the Idiopathic OAB Space Dampening Prospects
Xeomin – Will the “Pure” Factor Finds Many Takers?
Xeomin Takes Big Leap in the US
Xeomin’s Potential in the US Cosmetic Market
Merz Fortifies Position in the US Facial Injectables Market with BioForm Acquisition
PurTox Touted to Emerge as a Direct Competitor to Botox in the US
Competitive Landscape
Botox Leads the US Botulinum Toxin Market
Market Share Statistics
Table 16: US Market for Therapeutic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand – Botox, Myobloc, Dysport and Xeomin (includes corresponding Graph/Chart)
Table 17: US Market for Aesthetic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand – Botox and Dysport (includes corresponding Graph/Chart)
Product Approvals/Launches
Strategic Corporate Developments
Key Players
B. Market Analytics
Table 18: US Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 19: US Historic Review for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 20: US 15-Year Perspective for Botulinum Toxin by Application – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
2. EUROPE
A. Market Analysis
Current and Future Scenario
European BTX Cosmetics Treatments Market - A Primer
Botox Approvals and Indications in Select European Countries
Botox to Support Radiation Treatments
Botox Loses Market to New Entrants in Europe
Galderma’s Azzalure Makes Market Entry in Europe, Gains Share from Botox
Russia Mandates Registration of BTX Drugs
Market Share Statistics
Table 21: European Market for Therapeutic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand –Botox, Dysport, Xeomin, and Neurobloc (includes corresponding Graph/Chart)
Table 22: European Market for Cosmetic Neurotoxins (2011E): Percentage Breakdown of Revenues by Brand – Botox (Vistabel/Vistabex), Dysport and Xeomin (includes corresponding Graph/Chart)
Product Approvals and Launches
Strategic Corporate Development
Key Players
B. Market Analytics
Table 23: European Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic Applications and Therapeutic Applications Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 24: European Historic Review for Botulinum Toxin by Application –Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 25: European 15-Year Perspective for Botulinum Toxin by Application – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
3. REST OF WORLD
A. Market Analysis
Current and Future Scenario
A Peek into Select Markets
India – An Emerging Market for Botox
South Korean BTX Market – An Overview
Table 26: Botulinum Toxin Demand in South Korea: 2007- 2011E List of Botulinum Toxin Products Sold in South Korea by Year of Launch (includes corresponding Graph/Chart)
List of Botulinum Toxin Products Sold in South Korea by Year of Launch
Meditoxin Dominates Domestic BTX Market
Table 27: Korean Botulinum Toxin Market (2010): Percentage Breakdown of Sales by Leading Players -Medy-Tox, Allergan, Ipsen, and Lanzhou Institute (includes corresponding Graph/Chart)
Australia – A Well Supported Market
Botox Approvals and Indications in Select Asian Countries
Latin America- Cosmetic Surgery Market
Botox Approvals and Indications in Select Latin American Regions
Botox Approvals and Indications in Other Select Global Regions
Product Approvals and Launches
Strategic Corporate Developments
Key Players
B. Market Analytics
Table 28: Rest of World Recent Past, Current & Future Analysis for Botulinum Toxin by Application – Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 29: Rest of World Historic Review for Botulinum Toxin by Application – Cosmetic and Therapeutic Markets Independently Analyzed by Annual Sales Figures in US$ Million for the Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 30: Rest of World 15-Year Perspective for Botulinum Toxin by Application – Percentage Breakdown of Dollar Sales for Cosmetic Applications and Therapeutic Applications Markets for the Years 2004, 2011 & 2018 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 22 (including Divisions/Subsidiaries - 26)
Region/CountryPlayers
The United States
Japan
Europe
France
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan) Skip to top